Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | AKT1 | P31749 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16511729 | 1.00 | GAA (0.50) | GAAL3MBTL1LMNAAKT1KMT2A | |
| SCHEMBL16511705 | 0.82 | AKT1 (0.43) | GAAL3MBTL1AKT1KMT2ANPC1 | |
| SCHEMBL2134100 | 0.79 | GAA (0.41) | GAAL3MBTL1LMNAAKT1KMT2A | |
| SCHEMBL3418130 | 0.79 | GAA (0.41) | GAAL3MBTL1LMNAAKT1KMT2A | |
| SCHEMBL3418224 | 0.79 | GAA (0.41) | GAAL3MBTL1LMNAAKT1KMT2A | |
| SCHEMBL18190484 | 0.79 | GAA (0.41) | GAAL3MBTL1LMNAAKT1KMT2A | |
| SCHEMBL2133796 | 0.79 | GAA (0.41) | GAAL3MBTL1LMNAAKT1KMT2A | |
| SCHEMBL14837969 | 0.79 | CTSL (0.43) | GAAL3MBTL1LMNAAKT1KMT2A | |
| SCHEMBL19302749 | 0.77 | CTSL (0.41) | GAAL3MBTL1AKT1KMT2ANPC1 | |
| SCHEMBL3421084 | 0.75 | LMNA (0.38) | GAAL3MBTL1LMNAAKT1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103087054-A | 4-pyridyl phenyl ether compounds, and preparation method and application thereof | UNIV SHANDONG | 2013-05-08 | — | — | CN | claimed |
| CN-102911124-A | Hydroxy-pyrimidone compound and preparation method and application thereof | UNIV SHANDONG | 2013-02-06 | — | — | CN | claimed |
| US-10364256-B2 | Biaryl pyrazoles as NRF2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-30 | — | — | US | disclosed |
| US-20180282349-A1 | BIARYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-10-04 | — | — | US | disclosed |
| WO-2017060854-A1 | BIARYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-04-13 | — | — | WO | disclosed |
| CN-105001219-A | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME | 2015-10-28 | — | — | CN | disclosed |
| CN-103476258-A | Novel cyclic azabenzimidazole derivatives useful as antidiabetic agents | MERCK SHARP & DOHME | 2013-12-25 | — | — | CN | disclosed |
| CN-103087054-A | 4-pyridyl phenyl ether compounds, and preparation method and application thereof | UNIV SHANDONG | 2013-05-08 | — | — | CN | disclosed |
| CN-102911124-A | Hydroxy-pyrimidone compound and preparation method and application thereof | UNIV SHANDONG | 2013-02-06 | — | — | CN | disclosed |
| EP-1565457-A2 | PROCESS FOR SYNTHESIS BIS-ARYL DIAMIDOXIME COMPOUNDS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004051217-A2 | PROCESS FOR SYNTHESIS BIS-ARYL DIAMIDOXIME COMPOUNDS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10364256-B2 | Biaryl pyrazoles as NRF2 regulators | NFE2L2, KEAP1, NQO1 | GAA 2920/4885L3MBTL1 3899/4885LMNA 2758/4885 |
| US-20180282349-A1 | BIARYL PYRAZOLES AS NRF2 REGULATORS | NFE2L2, KEAP1, NQO1 | GAA 2920/4885L3MBTL1 3899/4885LMNA 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.